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PSA has been used as a biomarker for prostate cancer for a long time. To 
characterize different glycoforms of PSA using techniques like UHPLC and cIEF, 
concentration and purification of PSA from complex samples becomes necessary. Our 
group has developed submicron silica spheres based affinity beads to extract PSA 
through immunoprecipitation. This study focuses on measuring the bead performance 
when antibody type/amount was varied and PSA concentration was lowered for clinical 
use. To better satisfy the requirement of large-scale extraction, several attempts were 
made to increase the bead capacity. The results will be presented and future directions of 
the project will be discussed. 
1 
CHAPTER 1 INTRODUCTION 
1.1PSA Test Overview 
Early detection of cancer saves life. Current treatment strategies have higher 
probabilities to cure with earlier detection. However, conventional diagnostic methods 
such as mammography have not reached the expectation of sensitivity and specificity for 
detecting cancer at early stages. Biomarker is another important tool for detection and it 
seems more potential since it detects diseases in a molecular level. Possible biomarkers 
include mutated genes, abnormal amount of proteins, altered post-transcriptional 
modification
1
. The discovery that free DNA was present in the serum of cancer patients 
decades ago opened the era of serum test
2
. 
One of the established tests is the prostate specific antigen (PSA) test for prostate 
cancer. PSA is a glycoprotein produced predominantly by the prostate gland. It exists in 
the seminal fluid in an enzymatic active form and in the blood in three molecular forms: 
complexed PSA (cPSA) in which PSA covalently bound with α1-antichymotrypsin 
(ACT), non-complexed free PSA (fPSA) and active PSA entrapped by α-macroglobulins 
(α2-M) and pregnancy zone protein (PZP)
3
. The sum of fPSA and cPSA in serum is 
referred to as total PSA (tPSA). Moreover, some Pro or precursor forms of PSA (pPSA) 
in serum like [-2]proPSA are considered as potential biomarkers for prostate cancer. The 
PSA test measures the level of PSA in a man’s blood
4
. In the past, PSA levels of 4 ng/ml 
2 
or lower was considered normal while a man with a PSA level higher than 10 ng/ml was 
recommended a prostate biopsy to see whether prostate cancer was present. However, 
this method lacks specificity because an elevation in PSA can be caused by not only 
prostate cancer, but also a number of benign prostate conditions including prostatitis 
(inflammation of the prostate) and benign prostatic hyperplasia (BPH)
4
. To make better 
use of PSA to differentiate prostate cancer and benign conditions, researchers have 
investigated other aspects of PSA including fPSA percentage in tPSA, Prostate Health 
Index
5
 (Phi, a parameter combining tPSA, fPSA and [-2]proPSA), PSA density of the 
transition zone, age-specific PSA reference ranges and PSA level change velocity
6
. 
However, these methods fail to allow clear differentiation when PSA level is in the gray 
zone—between 4 and 10 ng/ml
7
. Recently, more and more research has been focused on 
the carbohydrate structure of PSA because there is evidence that the cellular 
glycosylation process, especially sialylation, is perturbed in tumors
8-10
, which might help 
in differentiating cancer from normal cells. For example, free PSA in serum from prostate 
cancer has been found to have a lower α2,6-linked sialic acid and higher α2,3-linked 
sialic acid than those from BPH
11
. 
In general, the analysis of PSA involves two steps: purification and characterization. 
Purification methods include chromatographic techniques that remove albumin and 
immunoglobulin from serum, and immunoprecipitation (IP) in which a protein (antigen) 
is precipitated out of solution using its antibody which can specifically bind to the 
particular protein
12







 and western blotting
16
. Some other characterization methods like 
immunoassays have no or not strong requirements on prior purification because they are 
3 
based on the highly specific interactions (e.g., antibody-antigen interaction). Traditional 












 and glycosylation immunosorbent assay(GISA)
12
. Current 
research on immunoassays has been focused on increasing efficiency by utilizing 
biofunctionalized nanoparticles (NPs). An example of such methods is the 
electrochemical immunoassay (EIA) which measures the changes in light, current, 




While immunoassays have the convenience of unnecessary purification and are 
reaching lower and lower limit of detection (LOD)
3
, most of them are focused on the 
quantification but are not informative of different glycosylation forms of PSA. Even 
though techniques like GISA are using different lectins to recognize different 
carbohydrate structures
12
, it is neither efficient nor practical to differentiate each of the 
~40 glycoforms
23
 of PSA in this way. On the other hand, techniques like UHPLC and 
mass spectrometry are getting more and more powerful in separating these glycoforms 
for either digested or undigested PSA
13
. To characterize PSA using these methods, our 
work is focused on purifying PSA using IP. This technique can be used to concentrate 
and isolate a protein from a complex sample, like serum, which contains thousands of 




In general, it can work in either direct way or indirect way: 
1) Direct capture: To capture the target protein, the corresponding antibody is 
immobilized on a solid-phase substrate. Then the substrate with bound antibodies is 
added to the protein mixture and the target protein is captured onto the substrate via the 
antibody. 
2) Indirect capture: The antibody is added directly to the protein mixture to bind its 
antigen (target protein), then the solid substrate coated in protein A/G (a type of protein 
that will bind the antibody) is added to the mixture and the antibody-antigen complex will 
stick to the substrate via the protein A/G. 
After capture, the target protein is released in harsh conditions, like in low pH buffer, 
and is collected for future analysis. The indirect approach is preferred when the protein 
concentration or the affinity constant is low and when the binding kinetics of the antibody 
to protein is slow. In other situations, the direct approach is more commonly used. To 
conduct either process, the solid substrate which offers sites to bind antibodies or protein 
A/G becomes vital: a good substrate should have high binding capacity, low background, 
fast binding rate and reasonable price. Chapter 1.2 will introduce the two most commonly 
used commercial substrates, or to say, affinity beads. 
 
1.2 Comparison of Commercialized Affinity Beads 
Agarose bead are the most widely used solid substrate for immunoprecipitation. It 
possesses a sponge-like, highly porous structure endowing itself with large surface to 
volume ratio, thus high binding capacity. But the side effect of such high binding 
5 
capacity is when the binding sites are not saturated with antibodies they will bind 
anything that will stick, thus elevating the background signal. The accompanying 
disadvantage with the porous structure is low density which makes it hard to precipitate 
and results in low recovery ratio. In addition, the variable pore size imposes an upper 
limit that may affect the binding of extremely large protein complexes to internal binding 
sites. 
A much newer alternative to agarose bead is the magnetic bead. Unlike the former, 
magnetic beads are solid spheres where antibodies can only bind to the surface, thus there 
is no limit on protein size. To compensate for the loss of capacity, magnetic beads usually 
have smaller size (1-4μm) than agarose beads (50-150μm). The highlight of this bead is 
the superparamagnetisum that makes the separation of beads from solution easier without 
vigorous centrifugation, thus helping maintain the structure and function of proteins. But 
the accompanying disadvantage is the high cost. Also, there is still space to lower bead 
size to reach higher capacity. 
The comparison of the two beads is also listed in Table 1.1. 
 
1.3 Development of Sub-Micron Silica Affinity Beads 
Our former group members have successfully designed a type of sub-micron silica 
spheres for immunoprecipitation/affinity extraction. We chose silica because 1) it is 
nontoxic, 2) its surface allows easy modification and 3) monodisperse silica particles 
with different size can be purchased. Basically, the silica spheres are coated with a mixed 
self-assembled monolayer, initiated by which a second layer of epoxy-activated 
6 
polyacrylamide has grown on the silica surface
13
 using atom transfer radical 
polymerization (ATRP) (Scheme 1.1a). The epoxy groups on the bead surface will react 
with the amino groups in the antibody (from either the N-terminal or lysine residue) so 
that the antibody can bind to the bead covalently without eluting with antigen in the final 
step (Scheme 1.1b). The polyacrylamide is highly hydrophilic thus can minimize non-
specific binding of proteins. Besides, it forms a brush layer that has been designed to be 
closely spaced to sterically exclude proteins hence protein-silanol interactions are 
avoided
24
. Our products try to beat commercial products in binding capacity by using 
small size (350 nm) particles. Compared with agarose, the solid sphere allows it to 
precipitate completely after centrifugation to reduce sample loss; compared with 
magnetic beads, silica is a common material and won’t cost much. 
So far the beads have been proved to be able to extract PSA without releasing 
antibody and minimize non-specific binding with the highly hydrophilic surface. 
However, the highest capacity is around 100ng PSA/mg beads, which has no advantage 
against commercial products. By increasing the capacity, more target proteins could be 
extracted using fewer beads, thus lowering the cost. Chapter 1.4 will discuss possible 
ways to increase bead capacity. Besides capacity which is measured when PSA is in 
excess, it is also a big concern how beads will perform when PSA is limited/of low 
concentration because in clinic use a man’s PSA level in blood is less than 1000 ng/ml
25
. 
Whether the recovery ability will keep constant in different concentrations will be 
answered in Chapter 4. 
 
7 
1.4 Possible Ways to Increase Bead Capacity 
The bead capacity might be increased in the following ways: 
The reaction conditions for affinity extraction are not fully optimized: the original 
time scale for each step is around 24h, which might lead to the loss of antibody activity. 
But inadequate incubation might result in an incomplete reaction either between beads 
and antibodies, or between antibodies and antigens. So a series of trials having different 
incubation time can be conducted to find the optimal time at each step. Besides, the 
fastest rate between the reaction of epoxy group and protein occurs at pH over 8 rather 
than 7 (what is currently used)
26
, which can help reaching the maximum capacity in 
shorter time. But higher pH is also suspicious of harming the antibody activity. So a 
combination of different pH and incubation time needs to be optimized for the first step 
(antibodies bind to beads). 
The Fab region of antibody has been blocked: Each antibody consists of two heavy 
chains and two light chains joined to form a “Y” shaped molecule (Scheme 1.2). The 
arms of the Y contain the sites that can bind two antigens, thus are called Fab region. The 
base of the Y consists of several constant domains pertaining to a particular type of 
antibodies and is called Fc region. The epoxy groups randomly react with the amino 
groups, both in the Fab and Fc region of the antibody since both of them could contain 
lysine (Scheme 1.3a). If the amino group in the Fab region is reacted, the antigen binding 
sites will be blocked and cannot be exposed to target protein. In turn, the bead capacity 
will be decreased. A possible solution is to attach protein G, an Fc binding protein, to the 
bead surface first, then use the system to attach antibody (Scheme 1.3b). But the problem 
8 
with this solution is that the interaction between protein G and antibody is not covalent so 
that antibody will be eluted when antigen is eluted. To solve this, crosslinking reagent 
can be added to covalently link Fc region and protein G
27
. But the reaction needs to be 
optimized so that the structure of Fab region will not be altered. 
The ratio of functional groups on bead surface is not fully optimized: the bead 
surface with a higher ratio of epoxy groups is more likely to react with antibodies, but 
also will become more hydrophobic. The hydrophobic surface is not favorable because it 
will increase the non-specific binding, thus lower the signal-to-noise ratio. In addition, it 
makes the beads hard to disperse and easy to agglomerate, thus exposing less surface area 
to react. So beads modified with different ratio of monomers can be compared to find the 
optimal ratio of functional groups. 
The epoxy group might not be the most efficient group to react with amino group: 
Currently, more and more research labs and companies are using N-Hydroxysuccinimide 
(NHS) as the functional group
28
 (Scheme 1.4). It could potentially decrease the time for 
reaction and increase the capability of beads. Besides, NHS is more hydrophilic than 
epoxy group, thus we could increase the ratio of functional groups on the surface without 
concerning that the beads will get hard to separate. 
1.5 Thesis Overview 
The work reported in this thesis focuses on applying the sub-micron silica affinity 
beads to extract PSA for follow-up analysis.  
 
9 
The first chapter reviews the current development of PSA test for prediction of 
prostate cancer and introduces immunoprecipitation (IP) as a purification method. Our 
group has developed a submicron silica based affinity beads as the solid substrates for IP, 
trying to overcome the shortcomings of two commercialized products. The limitation on 
bead capacity is also discussed as well as possible ways to improve. 
In Chapter 2, the reagents and procedures are listed and described for each step, 
including the preparation of surface-modified silica particles, characterization of the 
modified particles, extraction and detection of PSA, and extraction of model proteins. 
In Chapter 3, all the results by following the procedures in Chapter 2 are presented. 
SEM image shows the particles are homogenous around 350 nm in diameter; IR spectra 
show the polymerization occurs on bead surface. Next the prepared beads are used for 
extracting PSA 1) in different type/concentration of anti-PSA to see how bead capacity 
will change accordingly, 2) in lower concentration of PSA to see whether the recovery 
ability will hold. Then various efforts to increase bead capacity were presented, including 
optimizing the parameters in extraction, attaching protein G to bead surface prior to 
attaching antibody, adjusting epoxy group ratio on bead surface and replacing epoxy 
group with NHS group. 
Chapter 4 makes a conclusion on all the results presented in Chapter 3, points out 
any data that needs to be supplemented to draw more complete conclusions and discusses 
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Table 1.1 Comparison of Agarose beads and magnetic beads 
 













Mono or polydisperse 
Less sample handling 
No limit on protein size 












Scheme 1.1 Structure of silica affinity bead and its reaction with protein. a) The surface 
of the 350nm silica affinity beads is made of a mixed self-assembled monolayer (inner) 
and an epoxy-activated polyacrylamide layer (ourter) (provided by Dr. Yimin Hua). b) 




















Scheme 1.3 Attach antibodies to the bead surface a) antibodies are covalently attached to 
bead surface so that Fab region could be blocked (e.g., the bottom two molecules). b) 
antibodies are attached to bead surface via protein G (represented by the red spots) in a 



























CHAPTER 2 EXPERIMENTAL APPARATUS AND PROCEDURE 
2.1 Preparation of Surface-Modified Silica Particles 
 
2.1.1 Reagents 
Silica particles (500 nm in diameter) were purchased from Fiber Optic Center, Inc. 
(New Bedford, MA), and calcined at 600 ℃for 18 hours and then at 1050℃ for 3h. 
trichloromethylsilane (Gelest, Inc., Morrisville, PA), (chloromethyl)phenylethyl 
trichlorosilane (Gelest, Inc., Morrisville, PA), acrylamide (AAM, Sigma-Aldrich, St. 
Louis, MO), glycidyl methacrylate (GMA, Sigma-Aldrich, St. Louis, MO), methacrylic 
acid N-hydroxy succinimide ester (NHSMA, Sigma-Aldrich, St. Louis, MO), N-
Succinimidyl acrylate (NHSA, Tokyo Chemical Inc., Tokyo, Japan), CuCl (99.999%; 
Alfa Aesar, Ward Hill, MA), CuCl2 (99%; Acros Organics, Morris Plains, NJ), (+)-





, 5g of the freshly hydrolyzed silica particles were suspended 
in 300ml dry toluene solution containing 7 ml trichloromethylsilane and 1ml 
(chloromethyl)phenylethyl trichlorosilane and stirred under nitrogen overnight. The 
17 
reacted particles were then rinsed with dry toluene and allowed to dry in a vacuum oven 
at 60℃ overnight. The following surface-initiated polymerization could proceed in two 
different ways.  
The epoxy group was introduced by using Atom Transfer Radical Polymerization 
(ATRP): An deoxygenated solution containing AAM, GMA, CuCl, CuCl2 and Tris (2-
dimethylaminoethyl) amine (Me6TREN) in N,N dimethylformamide (DMF) was 
prepared as described earlier
1
.(CAUTION: acrylamide can be neurotoxic!) The silane-
modified particles were suspended in the solution and stirred under Argon for 7h. 
Although ATRP has been widely used in our lab to generate polymer layers on silica 
surface, it requires an inert atmosphere to protect Cu (I) catalyst and the glassware used 
to create such conditions is usually made in small size for lab use, which makes it 
inconvenient to operate and difficult to produce in large scale. Matyjaszewski’s group has 
reported an oxygen friendly version of ATRP, Activator Generated by Electron Transfer 
(AGET) ATRP, which allows ATRP to be performed in the presence of air
3
. Recently our 
group member Charu Yerneni has applied it to polymerize AAM on silica surface and his 
results have demonstrated that a similar PAAm brush layer was generated as synthesized 
by the traditional ATRP method. Thus the N-hydroxysuccinimide (NHS) group was 
introduced to the bead surface using AGET ATRP. The surface-initiated AGET ATRP 
was performed as following: A solution containing AAM, NHSMA or NHSA, CuCl2, 
Me6TREN and (+)-sodium L-ascorbate in isopropanol (IPA)-H2O (volume ratio = 1:1) 
was prepared. The silane-modified particles were suspended in the solution and stirred 
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under N2 for 2h. The modified particles were rinsed with DMF (for ATRP) or IPA-H2O 
mixture and allowed to dry in a dessicator. 
 
2.2 Characterization of the Modified Particles 
The particle size was measured using JEOL NeoScope JCM-5000 Scanning Electron 
Microscope (SEM). The surface modification was characterized using Bruker Tensor 37 
Fourier Transform Infrared Spectroscopy (FT-IR). 
 
2.3 Extraction of PSA 
 
2.3.1 Reagents 
Prostate specific antigen (PSA) was purchased from Lee Biosolutions (St. Louis, 
MO). Part of the PSA was labeled with Cy3 (GE Healthcare, UK) according to the 
labeling kit manual. A pair of capture and detection monoclonal antibodies for PSA was 
purchased from Fitzerald (Acton, MA). Protein G was purchased from Sigma-Aldrich (St. 
Louis, MO). Dimethyl pimelimidate dihydrochloride (DMP) and blocking buffer was 
purchased from Thermo Scientific (Rockford, IL). Phosphate buffered saline (PBS; 
0.01M, pH = 7.4), borate buffer (0.05M, pH=8.5), citrate buffer (0.1M, pH = 3.1), 
triethanolamine buffer (TEA buffer; 200mM, pH = 8.9), ethanolamine buffer (MEA 
buffer; 100mM, pH = 8.9) and elution buffer (0.1 M glycine with 2M urea, pH = 2.9) 




Scheme 2.1 illustrates the process of PSA extraction. The prepared beads were 
suspended in PBS buffer through sonication and vortex. Next the beads were resuspended 
in a diluted anti-PSA solution and incubated for reaction. Then the antibody coated beads 
were washed and separated from the solution through centrifuge. To block the remaining 
reactive sites and wash the antibodies attached to the bead surface through non-covalent 
binding, the beads were washed and incubated in the blocking buffer containing 
detergents. The washed and separated beads from last step were added to a diluted PSA 
solution and incubated for immunoprecipitation, after which the beads were separated 
and washed. Finally the beads were suspended in a small volume of citrate buffer via 
violent vortex to elute PSA. The beads were then centrifuged down while the citrate 
buffer solution containing PSA were collected for the following analysis. All the 
incubation steps were conducted at room temperature with slow tilt rotation. 
Protein G could be introduced to the bead surface prior to the antibody
4
: after the 
beads were suspended in PBS, they were resuspended in a diluted protein G solution and 
incubated for reaction. Then the protein G coated beads were washed and separated from 
the solution through centrifuge. To blocking the remaining reactive sites and wash the 
protein G attached to the bead surface through non-covalent binding, the beads were 
washed and incubated in the blocking buffer containing detergents. The washed and 
separated beads from the last step were incubated with anti-PSA, PSA and citrate buffer 
in turn as described in the normal extraction. To see the effect of crosslinking, after 
washed and separated from the anti-PSA solution, the beads were suspended in TEA 
buffer and mixed with a diluted TEA solution containing DMP
4
. After a short incubation, 
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the beads were separated from the solution and washed with TEA buffer. Then they were 
incubated with MEA buffer to block any unreacted DMP and washed with elution buffer 
to remove any uncrosslinked anti-PSA. Then the beads were washed by PBS buffer and 
incubated with PSA and citrate buffer in turn as described before. To better support the 
conclusion, three control groups were also conducted by removing either anti-PSA, 
protein G, or both (Table 2.1). 
 
2.4 Detection of PSA 
UHPLC analysis was performed using Thermo Accela UHPLC system with 
absorbance detection. BEH300 C4 column (1.7μm, 2.1 50mm) from Waters (Milford, 
MA) was used as the analytical column. A gradient of solvent A, water with 0.1% TFA 
and solvent B, acetonitrile with 0.1% TFA, was used. The chromatogram was obtained 
by an accumulation of absorbance from 200nm to 220nm. 










2.5 Extraction of Model Protein to Compare Bead Capacities 
 
2.5.1 Reagents 
All the necessary reagents could be found in Chapter 2.3.1 except trypsin inhibitor 
which was purchased from Sigma-Aldrich (St. Louis, MO) and was labeled with Cy5 
(GE Healthcare, UK) according to the labeling kit manual (labeled as Cy5-Trp). 
 
2.5.2 Procedures 
The prepared beads were suspended in PBS buffer through sonication and vortex, 
then resuspended in a diluted Cy5-Trp solution and incubated for reaction. Then the 
beads were centrifuged down and the supernatants were collected for fluorescence 
measurement using NanoDrop 3300 Fluorospectrometer (Wilmington, DE). The 
separated beads were first washed with blocking buffer and then with citrate buffer. After 





1 Xiao, D. and Wirth, M. Kinetics of surface-initiated atom transfer radical 
polymerization of acrylamide on silica. Macromolecules 35, 2919-2925 (2002) 
 
2 Zhang, Z., Ratnayaka, S. N., & Wirth, M. J. (2011). Protein UTLC-MALDI–MS using 
thin films of submicrometer silica particles. Journal of Chromatography A, 1218, 7196-
7202. 
 
3 Jakubowski, W., & Matyjaszewski, K. (2006). Activators Regenerated by Electron 
Transfer for Atom‐Transfer Radical Polymerization of (Meth) acrylates and Related 
Block Copolymers. Angewandte Chemie, 118, 4594-4598. 
 











Table 2.1 Experimental design to see the effect of protein G and crosslinking. 
 
Label Protein G Block 1 Anti-PSA Block 2 Crosslink PSA 
crosslink + + + + + + 
previous - - + + + + 
no Crosslink + + + - - + 
no Ab + + - - - + 
no Ab or ProG - + - - - + 
no ProG - + + - - + 
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CHAPTER 3 RESULTS AND DISCUSSION 
3.1 Silica Affinity Beads Characterization 
The silica affinity beads were prepared from 500 nm silica particles. SEM image 
(Figure 3.1a) shows that the particle size was homogenous and around 350 nm in 
diameter, perhaps due to calcinations. The FT-IR spectra (Figure 3.1b) show that efficient 
surface-confined polymerization occurred, with the evidence of carbonyl stretch in the 
amide at 1664 cm-1. 
To see whether the beads could extract PSA via immunoprecipitation instead of non-
specific binding, a control experiment was conducted in which no anti-PSA was added to 
the control group. The chromatogram (Figure 3.2) shows that no PSA was extracted in 
the control group, proving that 1) PSA was extracted through the interaction with anti-
PSA and thus anti-PSA was attached to the bead surface successfully while maintaining 
its activity,  2) the bead surface has good hydrophilicity to resist non-specific binding. 
 
3.2 Efficiency of Extracting PSA in Different Conditions 
The efficiency of extracting PSA could be different with different antibody/antigen 
type/concentration. To see the effect of antibody types, a pair of capture and detection 
monoclonal anti-PSA was used. This pair was originally utilized for the detection of free 
25 
PSA using enzyme-linked immunosorbent assay (ELISA), in which Cat# 10-P20A 
(affinity constant 	 7.5 10 / ) was the detection antibody 1  and Cat# 10-P21A 
(affinity constant 	 2.7 10 / ) was the capture antibody 2 . The chromatogram 
(Figure 3.3a) shows that both types of antibodies were able to extract PSA when attached 
to the bead surface but the capture antibody extracted around three times as much PSA as 
the detection antibody did according to the peak ratio. So the following experiments were 
all carried out using the capture antibody (Cat# 10-P21A). The difference in PSA amount 
could be partially due to the difference in affinity constant. The peak shape also looks 
slightly different, indicating that the two antibodies have different affinity towards 
different PSA glycoforms3. Using the same type of antibody (Cat# 10-P21A), the amount 
of antibody has a linear relationship with the amount of PSA that can be captured (Figure 
3.3b). When the added anti-PSA is more than 30 μg, the bead capacity (μg PSA extracted 
by per mg of beads) will be higher than 0.1 μg PSA/mg beads. To better satisfy the 
requirement of large-scale extraction, this value needs to be increased. And the effort of 
achieving higher capacities will be discussed in Chapter 3.3.  
While bead capacity mentioned above was measured when PSA was in excess (e.g., 
5 μg/ml 1 ml), in clinical use, PSA concentration in a man’s blood is less than 1000 
ng/ml4 and the gray zone of PSA concentration—4-10 ng/ml is of more interest5. Having 
known that about 10 mg beads could extract around 0.3 μg PSA from 1ml of 5 μg/ml 
PSA solution by using 10 μg anti-PSA (Figure 3.3b), a series of  trials were conducted to 
see if this efficiency still held in low PSA concentration solutions (400, 200, 100, 50, 25 
ng/ml). To ensure the same bead concentration, all the extractions, if not specified, were 
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conducted in the same volume—1 ml, so the PSA masses were 400, 200, 100, 50, 25 ng, 
respectively. Unexpectedly, the efficiency drops significantly when PSA concentration is 
reduced to 410 ng/ml (Figure 3.4), where only 122 ng was extracted instead of 348 ng 
that could be extracted from 5 μg/ml solution (Table 3.1). When concentration is 
decreased further, the amount of extracted PSA drops as well, but the recovery ratio 
actually increases. For concentrations lower than 210 ng/ml, the chromatograms fail to 
provide measurable peaks for the extracted PSA.  
To solve this, fluorescence quantification was used as an alternative in which PSA 
needed to be labeled with fluorescent dyes. The labeling might change the structure of 
PSA and in turn, affect its interaction with anti-PSA. To quantify this effect, similar 
concentrations of PSA and Cy3-PSA were extracted using the same amount of beads and 
anti-PSA. The chromatograms (Figure 3.5) and calculation results (Table 3.2) show that 
the labeling will weak the interaction, but a significant amount of PSA can still be 
extracted. So similarly, a series of low concentration Cy3-PSA solutions (670, 335, 167, 
84, 42 ng/ml) were extracted for fluorescence detection. The recovery ratio for the 670 
ng/ml trial is calculated to be 0.176, which is close to 0.154 obtained from chromatogram 
peak, thus strengthening the reliability of our data. When concentration is decreased to 
335 and 167ng/ml, the amount of extracted Cy3-PSA decreases but the recovery ratio 
increases, showing the same trend as the non-labeled PSA does. When the concentration 
is further decreased, the recovery ratio becomes abnormal (>1), a possible reason is that: 
when the concentration becomes small, the fluorescence intensity is too small to be 
measured; thus the solvent of solutions containing extracted PSA was evaporated through 
dry vacuuming and the protein was resuspended in a small volume (<5 μL) for 
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fluorescence measurement; the volume is so small that 1	μL error can cause >20% error 
in fluorescence intensities. In addition, to prove that the beads extract PSA via anti-PSA 
instead of non-specific binding, a control group with no anti-PSA added should be 
conducted. 
 
3.3 Efforts to Increase Capacity 
 
3.3.1 Optimize Extraction Conditions 
During the attachment of antibody, an important parameter is pH. As reported, the 
fastest rate between the reaction of epoxy group and protein occurs at pH over 86 rather 
than 7 (what we commonly used). But higher pH is also suspicious of harming the 
antibody activity. The chromatograms (Fig.3.6) show that when incubating beads with 
anti-PSA in two different pH buffers, the variation of bead capacity along with incubation 
time shares a similar pattern, which can be further proved by the plot of capacity against 
incubation time (Fig.3.7). But no matter how long the incubation time is, the capacity is 
always higher when incubating in PBS buffer (pH = 7.4) than in borate buffer (pH = 8.5), 
which indicates that even epoxy group may have a higher reaction activity at higher pH, 
the antibody works better at a more neutral pH. 
So far the pH for incubating with anti-PSA has been established, the effect of time for 
each step needs to be characterized. Generally speaking, with longer time, the reactions 
are closer to completion; but the activity of antibody might be lost as well. When 
incubating beads with anti-PSA for different time, the eluted PSA all have similar peak 
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shapes in the chromatogram (Figure 3.8a) and the capacity of beads gradually increases 
with the increase of time (Figure 3.8b). This appears controversial with Figure 3.7, where 
the maximum capacity occurs at 16 h. This can partially owe to detection error of 
UHPLC at such a tiny scale. Besides, when beads were incubated with blocking buffer or 
with PSA for different time, the peaks have similar shapes (Figure 3.8c, e). The trends of 
capacity change (Figure 3.8d, f) seem difficult to interpret partially due to detection error 
of HPLC, but both plots show the maximum occur at 24 h. The three time effects all 
indicate that a larger capacity occurs with a longer time scale and the maximum capacity 
might be beyond 24 h. 
 
3.3.2 Attach Protein G to Bead Surface Prior to Antibody 
Figure 3.9 shows the effect of attaching Protein G on bead capacity. When the beads 
are attached with protein G prior to anti-PSA without crosslinking (the blue line), there is 
PSA extracted, but the amount is less than what is extracted when only anti-PSA is 
attached (the red line) by comparing the peak areas. This can be explained by the loss of 
activity when Protein G is attached to the bead surface. But what is unexpected is that no 
anti-PSA is eluted together with PSA as the interaction between Protein G and anti-PSA 
is non-covalent. More data are needed to explain this phenomenon. In fact, crosslinking 
reagent (in this case, DMP) is used to prevent the elution of anti-PSA by covalently 
linking Protein G and anti-PSA7. But no PSA is extracted when DMP is added (the black 
line), probably because the amino groups within Fab region of anti-PSA reacted with 
DMP,  thus the structure got changed. The rest three trials are control groups: by 
comparing the pink line (neither anti-PSA nor Protein G was added) with the blue line, it 
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indicates that PSA is extracted not through the non-specific binding with the bead 
surface; by comparing the green line (no anti-PSA was added) with the blue line, it 
indicates that PSA is extracted not through the interaction with Protein G; by comparing 
the brown line (no Protein G was added) with the blue line, it indicates that anti-PSA is 
attached through the interaction with Protein G. In a conclusion, PSA is extracted through 
the bead_Protein G_anti-PSA_PSA interaction. 
 
3.3.3 Adjust Epoxy Group Ratio 
To see whether a lower ratio of epoxy groups on the surface could increase the bead 
capacity by improving its hydrophilicity, the monomer ratio of GMA and AAM was 
decreased to 1:40 (1:40 beads) and compared with the previous ratio of 1:20 (1:20 beads). 
The chromatograms (Figure 3.10) show that 1:20 beads have a larger capacity through 
the comparison of peak areas. To find the optimal ratio of monomers, more experimental 
data are needed. 
 
3.3.4 Replace Epoxy Group with NHS Group 
To see whether NHS group could increase the bead capacity, GMA was replaced with 
NHSA or NHSMA, both of which contain NHS group (Scheme 3.2). To see whether they 
could copolymerize with AAM on the bead surface, the monomer ratio NHSMA/NHSA 
to AAM was set to be 1 to 1 at first. The FT-IR spectra (Figure 3.11) show that different 
from pure AAM polymerization, the beads that were modified with mixed monomers 
have triplet within 1700-1850 cm-1, probably due to three different carbonyl stretches in 
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NHSMA/NHSA, thus indicating the successful copolymerization on the bead surface. In 
addition, the triplet for NHSMA is much higher than that for NHSA, indicating more 
NHS groups on bead surface. 
To compare the binding capacity of the NHS modified beads relative to epoxy 
modified ones, four types of beads (reacting with GMA and AAM, labeled GMA; 
reacting with NHSA and AAM, labeled as NHSA; reacting with NHSMA and AAM, 
labeled as NHSMA; reacting with only AAM, labeled as AAM) were used to extract a 
model protein—Cy5 labeled trypsin inhibitor (Cy5-Trp) from the same concentration of 
solution. After extraction, the suspensions were centrifuged and the supernatants were 
subjected to fluorescence detection. AAM has the largest fluorescent intensity because 
there is no functional group reacting with protein and it has the best hydrophilicity 
(Figure 3.12a). NHSA has almost no fluorescent intensity indicating that nearly all the 
proteins are attached to the bead surface, but the way of binding (covalent or non-
covalent) remains unknown. This can be answered by Figure 3.12b and 3.12c, where the 
fluorescent intensities of supernatants are still low after washing with blocking buffer and 
citrate buffer (pH=3.10), indicating most of the proteins are attached to NHSA beads in a 
covalent way. Interestingly, GMA beads and NHSMA beads don’t bind as much proteins 
as NHSA beads do (Figure 3.12a). Especially by comparing NHSMA beads and NHSA 
beads, this seems contradictory with the spectra in Figure 3.11 where the conclusion is 
made that NHSMA beads have more NHS groups on beads surface than NHSA beads. 
However, this can be explained by SN2 reaction mechanism: the reaction between NHS 
group and amino group happens when N in –NH2 attacks carbonyl group in NHSMA 
/NHSA monomer; because of the steric hindrance effect of the extra methyl group, the 
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reaction between NHSMA and protein is much slower than between NHSA and protein.  
Later, quite an amount of the protein was washed out with blocking buffer, indicating the 
significant existence of non-specific binding; quite amount of protein was washed out 
with citrate buffer for GMA beads, indicating the covalent binding between beads and 
protein is vulnerable to low pH. This could explain the peaks occurring one minute later 
than the PSA in some of the previous chromatograms (e.g., Figure 3.2): they are very 
likely to be anti-PSA, part of which eluted with PSA in the low pH condition. The strong 
binding ability, low non-specific binding and stable covalent interaction of NHSA bead 
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Scheme 3.2 Molecular formula of a) NHSA b)NHSMA. c) Reaction between NHS group 
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Figure 3.1 a) SEM image of surface-modified silica beads. Bead size shrank from 500 nm 
to around 350 nm after calcinations. b) FT-IR spectra of 350 nm silica beads modified 











Figure 3.2 Chromatogram of PSA extracted from 5μg/ml solution. Black line indicates 














































Figure 3.3 The effect of anti-PSA on the amount of extracted PSA.  a) The 
chromatograms of extracted PSA by using different types of anti-PSA.  b) The amount of 
Anti-PSA varies proportional to the amount of anti-PSA added by using 10.5 mg silica 






































































Amount of anti-PSA added (g)
y = 0.03189x + 0.00306
R2 = 0.9976
Using 10.5 mg silica affinity beads
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Table 3.1 Amount of PSA extracted from different concentrations of PSA and their 
corresponding recovery ratio calculated from the chromatogram peaks 
 
PSA(ng) in 1ml PBS Recovered PSA (ng) Recovery ratio 
205 86 0.420 
410 122 0.298 









Figure 3.5 Chromatograms of a) non-labeled PSA extracted from its 410 ng/ml solution 
b) Cy3-PSA extracted from its 670 ng/ml solution (The two runs were conducted in two 




Table 3.2 Amount of PSA extracted from labeled and non-labeled PSA and their 
corresponding recovery ratio calculated from the chromatogram peaks 
 
PSA in 1ml PBS (ng) Recovered PSA (ng) Recovery ratio 
410 (PSA) 122 0.298 
670 (Cy3-PSA) 103 0.154 
 
 










































Table 3.3 Amount of Cy3 labeled PSA extracted from different concentrations of Cy3-
PSA and their corresponding recovery ratio calculated from the fluorescence intensities. 
For the first two rows, the fluorescence intensities were measured directly from the 25μL 
citrate buffer solution containing eluted PSA; for the last three rows in the red box, as the 
concentrations were two low to be measured, the solutions were concentrated from 25μL 
to 3μL for measurement. The recovery ratio which was larger than one might be due to 
the mishandling with volume, which was too little to cause big errors. 
 
Cy3-PSA (ng) in 1ml PBS Recovered PSA (ng) Recovery ratio 
670 118.1 0.176 
335 103.7 0.309 
167 62.3 0.373 
84 158.2 1.88 





















































Figure 3.6 Chromatograms of extracted PSA when particles were reacted with anti-PSA 
in different pH and different time (A) Beads were reacted with anti-PSA in borate buffer 
(pH =8.5) for 8h, 16h and 24h, respectively. (B) Beads were reacted in PBS buffer 
(pH=7.4) for 8h, 16h and 24h, respectively. 
a b 
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Figure 3.7 Comparisons of bead capacities (μg of PSA that could be extracted by per mg 
of beads) when reacted with anti-PSA in different pH and time. The black spots indicate 
bead capacity when reacted in borate buffer (pH = 8.5) while the red spots indicate bead 
capacity reacted in PBS buffer (pH = 7.4). The data was calculated from the peak areas 
from Figure 3.6. 
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Figure 3.8 The effect of reaction time on bead capacities a), c), e) are chromatograms 
showing effect of antibody incubation time, blocking time and antigen incubation time, 
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Figure 3.9 Chromatograms showing the effect of Protein G on bead capacity. Red line 
(previous) represents the extracted PSA when using the previous method, that is, first 
attaching antibody, next blocking, then capturing PSA; blue line (no crosslink) is 
different from the red one in that Protein G attachment and blocking were carried before 
antibody and PSA interaction; black line (crosslink) is different from the blue one in that 
antibody was cross linked with Protein G before interacting with PSA; the rest three lines 
were the same as the blue line (no crosslink) except that no antibody was added (green 
line, no Ab), no Protein G was added (brown line, no ProG) or neither antibody nor 

































 no Ab or ProG
 no ProG
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Figure 3.10 Chromatograms of extracted PSA using beads modified with different ratio 
































Figure 3.11 FT-IR spectra of 350 nm silica particles modified with poly-AAM (black 
line), copolymerization of NHSMA to AAM (1 to 1 ratio, red line) and copolymerization 
























































Figure 3.12 Fluorescence intensities of supernatants a) after the beads were 
incubated with Cy5-Trp, b) after the beads were washed with blocking buffer, c) 
after the beads were washed with citrate buffer. The three steps were conducted in 
order. For the black line, beads modified with GMA and AAM were used; for the 
red line, beads modified with NHSA and AAM were used; for the blue line, beads 
modified with NHSMA and AAM were used; for the green line, beads modified 
with AAM were used. d) Photograph of four beads and their supernatants after the 




CHAPTER 4 CONCLUSION AND FUTURE DIRECTIONS 
4.1 Conclusion 
We have prepared a type of silica based affinity beads with homogenous size of 350 
nm in diameter and with a layer of epoxy-activated polyacrylamide on the surface. The 
beads were able to extract PSA from solution via anti-PSA on the surface while non-
specific binding was negligible due to the highly hydrophilic surface. The amount of PSA 
that could be captured depends on not only the type but also the amount of anti-PSA. In 
addition, the amount of PSA is proportional to the amount of anti-PSA. When the 
concentration of PSA is decreased, the amount that can be recovered decreases 
accordingly, but the recovery ratio increases in the observable range. 
To increase the capacity of beads, first the extraction conditions were optimized: it 
was found that a neutral pH in the step of attaching anti-PSA corresponds to a higher 
bead capacity than a higher pH does; among all the time scales that have been tried, the 
longest time (24 h) in each step corresponds to the highest bead capacity, but it remains 
unknown if capacity will keep increasing when the incubation time is longer than 24 h. 
Next, protein G was introduced to the system to see if it could help increase the bead 
capacity. The experiment results show that protein G does its job during the process, but 
decreases (instead of increases) the bead capacity. Crosslinking, on the other hand, leads 
to no PSA captured probably by eliminating the activity of anti-PSA. Then, when the 
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epoxy group ratio on the bead surface was decreased, bead capacity decreased as well, 
probably due to insufficient epoxy groups to act with. Finally, the epoxy group was 
replaced with NHS group. The preliminary experiments with model proteins show that 
beads modified with NHS group have a higher bead capacity through covalent binding 
than those modified with epoxy group. But whether it works for affinity extraction 
remains unknown. 
 
4.2 Future Directions 
To make the conclusions in Chapter 4.1 more solid, more data are needed: 
1) Since PSA extracted from low concentration solutions cannot be measured using 
either UHPLC or fluorescence, ELISA can be used as an alternative because of 
its low detection limit. 
2) More data is needed to explain why there is no anti-PSA eluted together with 
PSA when protein G is applied. If the interaction between anti-PSA and protein 
G is strong enough to resist the low pH, then crosslinking reagent becomes 
unnecessary. 
3) More data is needed to find the optimal ratio of GMA to AAM ratio, which can 
be either smaller than or larger than the current one (1:20). 
4) Apply the beads modified with NHSA/AAM for affinity extraction to see 
whether PSA could be captured. The ratio of NHSA to AAM can also be 
optimized because too dense NHS groups on the bead surface might change the 
structure of anti-PSA and affect its activity. 
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Besides, there are also some new directions worthy of trying: 
1) Indirect approach for immunoprecipitation
1
: In the context the direct approach is 
used, in which the antibodies are immobilized on the bead first and then the 
beads with bound antibodies are used to extract proteins. However, when the 
protein concentration is low, the indirect approach might be more effective: the 
antibodies are added to the target protein solution to form antibody-antigen 
complex; then the beads coated in protein G are used to extract the complex. 
2) Combined with cIEF: our ultimate goal is to analyze the PSA in human blood to 
predict prostate cancer, so it is necessary to combine the immunoprecipitation 
step with powerful analyzing techniques. Recently, Brian Wei in our group has 
applied a capillary based isoelectric focusing (cIEF) technique
2
 to separate 
different glycosylation forms of PSA. So the idea is: first extract PSA from 
human serum using our affinity beads, and then analyze it using cIEF. But the 
challenge is— for the current gray zone of PSA concentration, 4 – 10 ng/ml, and 
under the volume limit of blood sample we can take each time, how can we 
extract PSA with minimum sample loss, label it and inject it into the capillary. 
3) Combining with other affinity ligands: Besides anti-PSA, the affinity beads can 
be coated with other antibodies to capture corresponding target proteins. Besides 
antibodies, the affinity beads can be coated with lectins
3
—proteins which can 
bind specific carbohydrate molecules. Therefore the coated beads can be used to 
separate glycoproteins from non-glycosylated proteins, or one glycoform from 
another glycoform. The second application can be very meaningful when 
studying different glycoforms of PSA
4
. Furthermore, metal ions can be 
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introduced to the bead surface to purify specific proteins: cobalt, nickel and 
copper for the purification of histidine containing proteins or peptides; iron, zinc 
and gallium for the purification of phosphorylated proteins or peptides
5
. This 
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